U.S. Markets closed

ImmunoGen, Inc. (IMGN)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
6.53-0.04 (-0.61%)
At close: 4:00PM EDT

6.53 0.00 (0.00%)
After hours: 4:35PM EDT

People also watch
SGENIMMUEXELARRYINCY
  • C
    Crecy
    Crecy
    Bought IMGN- $6.70 yesterday. Great potential here with their Pipeline and Approved product. Excellent BuyOut potential too. My other stocks, AVEO recent Approved First line Renal Cell Cancer drug in the EU, major milestone due. ACRX Approval date Oct 12 for a very unique sublingual pain med, sufentanil.
  • C
    Chrissy
    Chrissy

    MDNA.TO (MC C$36 M) (Cash C$20 M) Hot Cancer Play with important Results in Q1 that could lead to FDA approval =1500-2000% UPSIDE Potential ! RALLYYYYYYYYYYY

    Brutally cheap and completely unknown canadian biotech stock with minimum 10 bagger potential . Positive Phase 2 results in recurrent glioblastoma which expected in Q1 2018 could lead to accelerated approval which would be a HUGE MAJOR milestones for this undiscovered low float stock . This company has brutally low valuation of only $36 million and most of that in cash $20 million which is enough untill Q1 2019 . This stock at $1.50 is a lifetime opportunity and we could see $15-20 easily on Positive 2 results and FDA approval .GL

    Medicenna Therapeutics (MDNA.TO)

    Market Cap C$36 Million
    Cash : C$ 20 Million << enough untill Q1 2019
    Price : $1.50

    Shares Out: 24.3 Million ( 15.5 Million shares held by Insider alone )

    Medicenna Therapeutics (TSXV: MDNA) CEO: Our Drug Has Potential for Phase 2 Approval
    https://smallcappower.com/videos/companies-to-watch/medicenna-therapeutics-tsxv-mdna/

    New Presentation
    http://s21.q4cdn.com/710416940/files/doc_presentations/2017/Medicenna-Corporate-Presentation-Q3-2017.pdf

    Fact Sheet
    http://s21.q4cdn.com/710416940/files/doc_downloads/fact_sheet/Medicenna-FS-Q1-2017-v2.pdf

    Insider Ownership :

    Aries Biologics, Inc. 5 500 000
    Rosemina Merchant 5 050 000
    Fahar Merchant 5 050 000
    Elizabeth Williams 5 300
    Chandrakant J. Panchal, PhD 1 000
    Trevor P. Wong-Chor 714

    Medicenna Therapeutics (TSXV: MDNA) CEO: Our Drug Has Potential for Phase 2 Approval
    Medicenna Therapeutics Corp. (CVE:MDNA) President & CEO Fahar Merchant said the Company received a large grant from the state of Texas.
    smallcappower.com
  • F
    Frank
    Frank
    Load up next stop is 10
  • S
    Sophia
    Sophia
    Have you heard anything about the*stock-dork yet? Their tips and articles have really improved my trades as of late. Check them out now at the*stock-dork .
  • B
    Biogemfinder
    Biogemfinder
    Like the great Mike Tyson once said, "everyone has a plan 'til they get punched in the mouth"
  • m
    mark
    mark
    Keep selling I will gladly buy more, lower please.
  • j
    james
    james

    https://stockpressdaily.com/bark-or-bite-what-is-the-street-consensus-on-immunogen-inc-nasdaqimgn/

    Analysts on a consensus basis are expecting that the stock will reach $9.29 within the year.

    Bark or Bite? What is The Street Consensus on ImmunoGen, Inc. (NASDAQ:IMGN) – Stock Press Daily
    stockpressdaily.com
  • J
    James Dean
    James Dean
    MACD crossed over, RSI, MFI, DMI are all weak while ROC has increased somewhat. Tells me this one has some more runway to drop in price. Great company, I'm a long, just reading the technical indicators.
  • B
    BobDole
    BobDole
    LOL
  • C
    Crecy
    Crecy

    As much as I dislike MF this is an interesting article.
    https://www.fool.com/investing/2017/09/16/is-immunogen-running-out-of-steam-or-taking-a-brea.aspx?yptr=yahoo

    Is ImmunoGen Running Out of Steam, or Taking a Breather? @themotleyfool #stocks $IMGN, $JAZZ
    www.fool.com
  • B
    BobDole
    BobDole
    Just got to doing the math.
    100M debt reduced to 23.6M debt
    Shares increases from 89.6M by 16.5M + [X]M to 106.1M +[X]M shares.
    Let's assume this is 5M shares, so we have 111.1M outstanding shares.

    Let's take the $8 share price right before this news hit and do the math. We have:

    89.6/111.1 x $8 = $6.45

    However, because debt is reduced greatly, we have:

    76.4M/111.1M shares = 0.69 shareholder equity increased

    $6.45 + $0.69 = $7.14?
  • A
    Albert88
    Albert88
    Is this selling done yet?.I am ready to buy more
  • A
    Ameen
    Ameen
    This Is heading to 5
  • M
    Mike
    Mike
    Dilution of some 20M+ shares causing a share reduction of some 20+%
  • j
    james
    james

    https://stockpressdaily.com/bark-or-bite-what-is-the-street-consensus-on-immunogen-inc-nasdaqimgn/

    Bark or Bite? What is The Street Consensus on ImmunoGen, Inc. (NASDAQ:IMGN) – Stock Press Daily
    stockpressdaily.com
  • M
    Mike
    Mike
    TIMBER ..
    Shares are so much more diluted.. could go to 2
  • m
    mark
    mark
    wow, great stock! Love when we get 10 % corrections on no news
  • M
    Michael
    Michael
    $7.25 is a support zone, could see a bounce back to the 8 area... then we'll see what happens if we get there.
  • M
    Michael
    Michael
    Biggest Loser on my screen today... Again...
  • M
    Mike
    Mike
    I love seeing the shorts show up, thats how you know its getting ready to have a big upside. By the time they reach the message board theyve missed the short run. hahahahahhaha sitting by waiting for them to get burned.